Biopharma Corporate Development, Licensing & rNPV Valuation
Biotech Clinical Phase POS & Risk-Adjusted rNPV Formula
Calculate Biopharma Cumulative Likelihood of Approval LOA = P_Ph1 * P_Ph2 * P_Ph3_NDA, Risk-Adjusted Commercial Launch PV, Pipeline Asset Risk-Adjusted Net Present Value (rNPV), and Breakeven Approval Probability.
Value clinical-stage drug candidates with explicit phase-gate probabilities—never inflated 45% discount rates!
Early-stage biotech analysts often make the fatal mistake of discounting unrisked blockbuster revenues at an arbitrary 40%–50% "venture WACC"—conflating binary clinical trial attrition with the time value of money! Institutional pharma business-development teams instead use Risk-Adjusted Net Present Value (rNPV): discount cash flows at a normal pharma cost of capital (9%–11%), multiply Unrisked Post-Approval Commercial PV by Cumulative Likelihood of Approval LOA = P(Phase 1->2) * P(Phase 2->3) * P(Phase 3->FDA Approval), and subtract Phase-Gated Expected Clinical Trial R&D PV! Passing a single clinical readout immediately resets that completed phase’s probability to 1.00, producing a transparent step-function jump in rNPV!
Verify on a Phase-1 Oncology Asset—Phase_1_Transition_Prob = 0.60 (B2), Phase_2_Proof_of_Concept_Prob = 0.35 (B3), Phase_3_&_NDA_Approval_Prob = 0.50 (B4), Unrisked_Commercial_Launch_PV = $800.00M (B5), and Risked_Clinical_Trial_R&D_PV = $44.00M (B6): Cumulative LOA is 0.60 * 0.35 * 0.50 = 0.1050 (10.50% in E2); Risk-Adjusted Commercial PV is $800.00M * 0.1050 = $84.00M (E3); Pipeline Asset rNPV is $84.00M - $44.00M = $40.00M (E4); and Minimum Breakeven LOA is 44 / 800 = 0.0550 (5.50% in E5)!
| Biopharma rNPV Metric (Ph1=60%, Ph2=35%, Ph3/NDA=50%, Launch PV=$800M, R&D=$44M) | Formula | Verified Output |
|---|---|---|
| Cumulative Approval Probability LOA | P_Phase1 * P_Phase2 * P_Phase3_NDA | 0.1050 (0.1750 Post-Ph1 Readout) |
| Risk-Adjusted Commercial PV ($M) | Unrisked_Launch_PV * Cumulative_LOA | $84.00M ($140.00M Post-Ph1) |
| Pipeline Asset rNPV ($M) | Risked_Commercial_PV - Risked_RD_PV | $40.00M ($96.00M Post-Ph1) |
| Breakeven LOA Hurdle | Risked_RD_PV / Unrisked_Launch_PV | 0.0550 (5.50% Minimum LOA) |
Biotech Pipeline Risk-Adjusted Net Present Value (rNPV) Formula
Validate phase probabilities in (0, 1], Unrisked_Launch_PV > 0, and non-negative Risked_RD_PV!
=LET(p_s1, B2, p_s2, B3, p_s3, B4, cm_v, B5, rd_v, B6, IF(OR(p_s1 <= 0, p_s1 > 1, p_s2 <= 0, p_s2 > 1, p_s3 <= 0, p_s3 > 1, cm_v <= 0, rd_v < 0), "Invalid Clinical rNPV Input", LET(lo_a, p_s1 * p_s2 * p_s3, ROUND(cm_v * lo_a - rd_v, 2))))Positive Phase-1 Readout Value Inflection Check (Set Phase-1 POS = 1.00)
Simulate successful Phase-1 completion by setting B2 = 1.00: Cumulative LOA E2 jumps to 0.1750 (17.50%), Risked Commercial PV E3 reaches $140.00M, and Asset rNPV E4 more than doubles from $40.00M to $96.00M!
=IF(ISTEXT(E4), E4, ROUND(B2 * B3 * B4, 4))Try the example
Use the original values or change them to test your understanding.